文献速递治疗药物监测与药物基因组学特殊人群用药

CYP3A5基因型对心脏移植受者他克莫司剂量需求及谷浓度影响的队列研究

Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients.
PubMed 文献 · Pharmacotherapy · 2026-01-01

该回顾性队列研究纳入33例心脏移植受者,发现CYP3A5表达者达到治疗性谷浓度所需时间更长(14天 vs 7.5天,p=0.0073),且达到目标浓度所需他克莫司剂量近乎翻倍(10 mg/天 vs 5 mg/天,p=0.0019),而C0/D在非表达者中近乎高2倍(2.0 vs 1.1 ng/(mL*mg),p=0.0015)。除慢代谢者术后1周血肌酐升高更明显(p=0.047)外,1年临床结局无显著差异。

要点

  • CYP3A5表达者达到他克莫司治疗浓度更慢且需更高剂量。
  • 非表达者剂量校正谷浓度近乎高2倍。
  • 除慢代谢者术后1周血肌酐升高更明显外,1年临床结局无显著差异。

核心结论

  • CYP3A5表达状态影响心脏移植受者达到他克莫司治疗浓度所需时间和剂量需求。
  • CYP3A5指导的给药策略可能有助于更快达到治疗性他克莫司浓度。

研究设计与样本

  • 收集他克莫司剂量、浓度、 demographics、CYP3A4/5基因型、合并用药及生化数据。
  • 主要结局为首次达到治疗性谷浓度的时间,按CYP3A5表达状态比较。

主要发现

  • CYP3A5表达者(27.3%)达到治疗性谷浓度时间中位数14天(Q1,Q3:9.5,16),非表达者7.5天(6.0,11),p=0.0073。
  • 达到目标浓度所需他克莫司剂量:表达者10 mg/天(5.5,13),非表达者5 mg/天(3.3,5.9),p=0.0019。
  • C0/D非表达者2.0 ng/(mL*mg)(1.6,3.4),表达者1.1 ng/(mL*mg)(0.83,1.7),p=0.0015。
  • 逐步回归识别给药途径(舌下vs口服)和初始剂量为所有结局的协变量。
  • 慢代谢者术后1周血肌酐升高更明显(p=0.047)。

关键数值与推荐

  • 临床药物遗传学实施联盟建议CYP3A5表达者初始剂量增加1.5至2倍以改善移植结局。

临床怎么用

  • 对心脏移植受者可考虑根据CYP3A5基因型调整他克莫司初始剂量以更快达到治疗浓度。
  • CYP3A5表达者可能需要更高剂量和更长监测时间。

局限性

  • 样本量较小(33例)。
  • 回顾性设计。
  • 单中心数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tacrolimus is primarily metabolized by Cytochrome P450 (CYP)3A4/5. The Clinical Pharmacogenetics Implementation Consortium recommends increasing the initial dose 1.5- to 2-fold in CYP3A5 expressers to enhance transplant outcomes. Our objective was to investigate the impact of CYP3A5 expresser status on tacrolimus dosing requirements and attainment of target trough concentrations in heart transplant recipients. METHODS: We performed a retrospective cohort analysis of tacrolimus dose, concentration, demographics, CYP3A4/5 genotype, concomitant medications, and biochemical data in heart transplant recipients from December 2020 to August 2023. The primary outcome was the time to first therapeutic trough concentration, compared by CYP3A5 expression status. Secondary outcomes included the tacrolimus dose at target trough and dose-adjusted tacrolimus trough concentration (C0/D). Stepwise multiple regression was performed to account for potential covariates. Moreover, clinical outcomes were assessed at 1-year post-transplantation and compared based on CYP3A5 expression status. RESULTS: Among 33 patients, CYP3A5 expressers (27.3%) required longer to achieve therapeutic trough concentrations (median [Q1, Q3]: expressers: 14 [9.5, 16] days vs. nonexpressers 7.5 [6.0, 11] days; p = 0.0073) and required nearly double the tacrolimus dose to reach target concentrations (10 [5.5, 13] mg/day for expressers vs. 5 [3.3, 5.9] mg/day for nonexpressers; p = 0.0019). Conversely, the C0/D was nearly 2-fold higher in nonexpressers 2.0 [1.6, 3.4] ng/(mL*mg) than expressers (1.1 [0.83, 1.7] ng/(mL*mg); p = 0.0015). Stepwise regression identified route of administration (sublingual vs. oral) at therapeutic trough and initial dose as covariates for all outcomes. All clinical outcomes showed no significant differences based on CYP3A5 expression status, with the exception that poor metabolizers demonstrated higher serum creatinine elevation at 1-week post-transplantation (p = 0.047). CONCLUSION: Our findings highlight the impact of CYP3A5 expresser status on the time needed and dosing requirements to attain tacrolimus therapeutic concentrations in heart transplant recipients, suggesting CYP3A5-guided dosing strategies may improve rapid attainment of therapeutic tacrolimus concentrations.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Wu Y, Eadon MT, Schenkelberg L, et al. Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients. Pharmacotherapy. 2026. PMID: 41660740. doi:10.1002/phar.70116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。